Deseret Mutual Benefit Administrators Raises Stock Position in Organon & Co. (NYSE:OGN)

Deseret Mutual Benefit Administrators boosted its position in shares of Organon & Co. (NYSE:OGN) by 24.3% during the fourth quarter, Holdings Channel.com reports. The firm owned 6,256 shares of the company’s stock after buying an additional 1,222 shares during the quarter. Deseret Mutual Benefit Administrators’ holdings in Organon & Co. were worth $93,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Prospera Private Wealth LLC purchased a new position in Organon & Co. during the third quarter worth about $25,000. Horizon Bancorp Inc. IN raised its stake in Organon & Co. by 2,401.5% during the fourth quarter. Horizon Bancorp Inc. IN now owns 1,651 shares of the company’s stock worth $25,000 after purchasing an additional 1,585 shares during the period. Abich Financial Wealth Management LLC raised its stake in Organon & Co. by 5,646.3% during the third quarter. Abich Financial Wealth Management LLC now owns 2,356 shares of the company’s stock worth $45,000 after purchasing an additional 2,315 shares during the period. MassMutual Private Wealth & Trust FSB raised its stake in Organon & Co. by 32.4% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 2,749 shares of the company’s stock worth $41,000 after purchasing an additional 672 shares during the period. Finally, Versant Capital Management Inc raised its stake in Organon & Co. by 92.2% during the fourth quarter. Versant Capital Management Inc now owns 2,760 shares of the company’s stock worth $41,000 after purchasing an additional 1,324 shares during the period. 77.43% of the stock is owned by hedge funds and other institutional investors.

Organon & Co. Price Performance

Organon & Co. stock opened at $15.47 on Friday. The company has a debt-to-equity ratio of 17.73, a quick ratio of 1.21 and a current ratio of 1.70. The company has a market capitalization of $3.98 billion, a price-to-earnings ratio of 4.64, a price-to-earnings-growth ratio of 0.90 and a beta of 0.76. The company’s 50 day simple moving average is $15.36 and its 200-day simple moving average is $17.27. Organon & Co. has a 1 year low of $13.87 and a 1 year high of $23.10.

Organon & Co. (NYSE:OGN) last announced its quarterly earnings data on Thursday, February 13th. The company reported $0.83 earnings per share for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.09). The business had revenue of $1.59 billion during the quarter, compared to analyst estimates of $1.57 billion. Organon & Co. had a net margin of 13.49% and a return on equity of 431.62%. As a group, equities research analysts expect that Organon & Co. will post 3.68 earnings per share for the current year.

Organon & Co. Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 13th. Investors of record on Monday, February 24th will be issued a $0.28 dividend. This represents a $1.12 dividend on an annualized basis and a dividend yield of 7.24%. The ex-dividend date of this dividend is Monday, February 24th. Organon & Co.’s dividend payout ratio (DPR) is currently 33.63%.

Analyst Ratings Changes

A number of brokerages have commented on OGN. TD Cowen raised shares of Organon & Co. to a “hold” rating in a research note on Wednesday, January 15th. Barclays reduced their price target on shares of Organon & Co. from $26.00 to $24.00 and set an “overweight” rating on the stock in a research note on Friday, February 14th. Finally, Morgan Stanley reduced their price target on shares of Organon & Co. from $17.00 to $16.00 and set an “equal weight” rating on the stock in a research note on Friday, February 14th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Organon & Co. presently has an average rating of “Hold” and a consensus price target of $20.80.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.